跳转至内容
Merck
CN

H-102

Supelco

4-羟基杜洛西汀-β-D-葡萄糖醛酸苷 溶液

100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C24H27NO8S
分子量:
489.54
MDL编号:
UNSPSC代码:
41116107
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

certified reference material

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

100 μg/mL in methanol

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

clinical testing

包装形式

single component solution

储存温度

−20°C

一般描述

4-Hydroxyduloxetine glucuronide is a metabolite of duloxetine. Duloxetine, marketed in the US under the trade name Cymbalta® is a serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder and to alleviate pain associated with diabetic neuropathy, fibromyalgia, and osteoarthritis. This Certified Spiking Solution® is applicable for use in applications such as clinical toxicology, urine drug testing, and forensic analysis by LC-MS/MS or GC/MS.

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Cymbalta is a registered trademark of Eli Lilly and Co.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

警示用语:

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

靶器官

Eyes

储存分类代码

3 - Flammable liquids

WGK

WGK 2

闪点(°F)

49.5 °F - closed cup

闪点(°C)

9.7 °C - closed cup

法规信息

危险化学品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

M A Smit et al.
Oncogene, 30(35), 3735-3744 (2011-04-12)
Anoikis (detachment-induced apoptosis) prevents the survival of cells at inappropriate sites of the body and can therefore act as a barrier to metastasis. In a function-based genome-wide screen, we have previously identified the neurotrophic tyrosine kinase receptor TrkB as a
Deyin Xing et al.
Cancer research, 69(21), 8231-8235 (2009-10-22)
Uterine leiomyosarcoma (ULMS) is a rare gynecologic malignancy with a low survival rate. Currently, there is no effective treatment for ULMS. Infrequent occurrences of human ULMS hamper the understanding of the initiation and progression of the disease, thereby limiting the

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持